BEAUACTIVE - manual.pchi-china.com

BEAUACTIVE®

Corrects both conspicuous facial pores and age spots

What are conspicuous facial pores and age spots?

Multi-target mode of action

Many people over the age of 30 complain about the appearance of conspicuous large facial pores and age spots*. Two important factors in pore enlargement are damage from the sun’s UV rays and reduced cell quality, both of which weaken the skin’s natural collagen. This leads to sagging skin resulting in larger looking facial pores, also called conspicuous pores. If skin receives chronic exposure to sunshine, melanocyte activity will increase and an irregular amount of melanin will be produced. The result will be the appearance of age spots on the most commonly exposed areas, such as the face, hands and décolleté. The BEAUACTIVE® multi-target mode of action addresses both conspicuous pores and age spots.

1) In the in silico model BEAUACTIVE® docks into PPARα, a master cell regulator whose activation influences multiple targets.

2) BEAUACTIVE® improves cell protection by reducing the production of UV-induced sunburn cells.

3) BEAUACTIVE® decreases UV stress marker p53 leading to reduced production of melanin. It is therefore effective at correcting age spots.

4) BEAUACTIVE® decreases UV-induced MMP expression and increases Collagen I and III to help in the reduction of conspicuous facial pores.

*DSM survey 2014

Conspicuous facial pores and age spots trouble people after the age of 30

Key facts

Unique product features• High purity, sustainable Hydroxystearic acid • Manufactured using green technology• Activates the master cell regulator PPARα in vitro • Strong Collagen I and III stimulation ex vivo• Prevents UV-induced expression of MMP-1 ex vivo• Reduces formation of UV-induced sunburn cells ex vivo• Reduces UV stress marker p53 ex vivo

Benefits

• Visibly reduces the appearance of conspicuous facial pores

• Visibly reduces the appearance of age spots• Makes skin look younger and improves

appearance after the age of 30

Cosmetic application

• Conspicuous facial pore applications• Age spot corrector creams

Suggested concentration

• Up to 1% BEAUACTIVE®

INCI name (active)

• Hydroxystearic acid

Most people looking for beautiful skin think first of eliminating lines and wrinkles. But other concerns, such as conspicuous facial pores and age spots, may be equally troubling. These arise after the age of 30 and are mainly caused by the aging process, exacerbated by sun damage. They have the effect of making people feel less attractive, particularly given their association with aging. Many consumers seeking solutions try a vast array of products, only to find them ineffective.

DSM is addressing these concerns with BEAUACTIVE®, a potent Hydroxystearic acid of high purity which is manufactured using green technology. DSM researchers discovered that, in vitro, BEAUACTIVE® activates the master cell regulator PPARα which triggers multi-target effects for better skin. Upon UVB stress BEAUACTIVE® hinders the production of both sunburn cells and the stress marker p53 which can increase skin pigmentation. BEAUACTIVE® also helps the skin to make more collagen, a key structural factor in the prevention of conspicuous facial pores. In vivo studies have confirmed the outstanding efficacy of BEAUACTIVE® which results in a visible reduction of conspicuous facial pores and age spots, giving skin a younger, improved appearance after the age of 30.

Efficacy

Colla

gen

I (fo

ld in

duct

ion)

5.0

4.0

3.0

2.0

1.0

0.0

BEAUACTIVE® (%)ControlTGFβ 10ng/ml

**

0.000039 0.000018

**

Medium

+98%**

0.000150

7.3

In vitro

** p<0.01 significance vs. medium control

Selected age spot of Subject #20 treated with 1% BEAUACTIVE®

Visibly reduced age spot contrast

Time = 0 Time = 4 weeks Time = 8 weeks

Time = 0 Time = 4 weeks Time = 8 weeks

Projection axis using false colors

Cross-polarized images

High LowMedium

Pigmentation

In vivo Eight-week placebo-controlled, double blind study37 volunteers (aged 38–65, mean 53.4 yrs) received product with 1% BEAUACTIVE®

38 volunteers (aged 34–65, mean 54.4 yrs) received the placebo formulation

Volunteers had to apply their respective test formulation to the whole face twice daily (mornings and evenings) for 8 weeks

The assessment methods used were: 1. High resolution photos (VISIA CR) and 2. Image analysis (pores and age spots)

Significant stimulation of Collagen I at very low concentrations

+98%Collagen I stimulation

• Key factor in correction of conspicuous facial pores Tests performed on primary human dermal fibroblasts

Time = 0 Time = 4 weeks Time = 8 weeks

-10% -29%

Reduction of segmented pore surfaces (blue)

Visibly corrects the appearance of conspicuous

facial pores

Colla

gen

III s

core

6000

5000

4000

3000

2000

1000

0

**

**

BEAUACTIVE® (%)Vehicle Control

+57%

0.01 0.1

** p<0.01 significance vs. vehicle control

Ex vivo

** p<0.01 significance vs. vehicle + UVB control

p53 reduction

• Key UV stress marker for cell damage

• Trigger for skin pigmentation Tests performed on p53 IHC stained skin sections by image analysis

p53

scor

e

25

20

15

10

5

0

**

BEAUACTIVE® (%)Controls

Untreatedw/o UV

Vehicle+ UVB

0.01

-46%

+ UVB (1 J/cm2)

Significant reduction of

UV-induced P53 -46%

Reduction of UV-induced

sunburn cells -49%

MM

P-1 g

ene

expr

essi

on (f

old

chan

ge) 6000

5000

4000

3000

2000

1000

0

BEAUACTIVE® (%)Controls

*

0.1

*

0.01

*

Sunscreen8 mg/cm2

Vehicle+UVB

Untreated w/o UV

-83%

+ UVB (1 J/cm2)

* p<0.05 significance vs. vehicle + UVB control

MMP-1 reduction

• Key factor in correction of conspicuous facial pores

UVB-induced (1J/cm2) MMP1 gene expression from skin section by RT-qPCR after one day

Significant reduction of

UV-induced MMP-1 expression

-83%

Significant stimulation of

Collagen III+57%

Sunb

urn

cells

sco

re

0.8

0.6

0.4

0.2

0

BEAUACTIVE® (%)Controls

0.01Sunscreen8 mg/cm2

Vehicle+UVB

Untreated w/o UV

0.1

-49%

+ UVB (1 J/cm2)

Sunburn cell reduction

• Key marker for photo-protection in the epidermis

Tests performed on stained skin sections 24 hours after UVB irradiation

Collagen III stimulation

• Key factor in correction of conspicuous facial pores

Tests performed on IHC stained sections

© 2017 DSM Nutritional Products, 4002 Basel, Switzerland. www.dsm.com/personal-careAll rights reserved. No part of this brochure may be reproduced, distributed or translated in any form or by any means, or stored in a database or retrieval system, without the prior written permission of DSM Nutritional Products AG (“DSM”). While making reasonable efforts to ensure that all information in this brochure is accurate and up to date, DSM makes no representation or warranty of the accuracy, reliability, or completeness of the information. Use of this information shall be at your discretion and risk. Nothing herein relieves you from carrying out your own suitability determinations and tests and from your obligation to comply with all applicable laws and regulations and to observe all third party rights. The uses and claims for DSM’s products recommended in the brochure should be adapted to the current local regulatory environment. We disclaim any and all liability in connection with your product or its use.

P0085

EuropeDSM Nutritional Products Europe Ltd.P.O. Box 2676, 4002 BaselSwitzerlandPhone: +41 61 815 7777Fax: +41 61 815 7860Email: [email protected]

Asia PacificDSM Singapore Industrial Pte Ltd.trading as DSM Nutritional Products Asia Pacific30 Pasir Panjang RoadMapletree Business City #13-31Singapore 117440Phone: +65 6632 6617Fax: +65 6632 6600 Email: [email protected]

North AmericaDSM Nutritional Products, LLC45 Waterview Boulevard, Parsippany, NJ 07054United States of AmericaPhone: +1 800 526 0189Fax: +1 973 257 8580Email: [email protected]

Latin AmericaDSM Produtos Nutricionais Brasil S.A. Avenida Engenheiro Billings, 1729 – Prédio 31Sala A - CEP:05321-010, São Paulo – SP BrasilPhone: + 55 11 3760 6409Fax: + 55 11 3760 6492Email: [email protected]